London: Oxford University Press (OUP) Monday launched a new logo which, it said, is designed to support its ongoing transformation to become a digital-first...
Hyderabad: After the Delta and Delta Plus variants of the Covid-19, a new strain – Kappa – has been discovered and three people infected...
Plant symbiosis with nitrogen-fixing soil bacteria (rhizobia) is a key to sustainable agriculture.
The hack is understood to have taken place in the middle of the month, but it is not clear who is behind the attack.
Covishield is the brand name for the AstraZeneca-Oxford University COVID-19 vaccine.
AstraZeneca said it is yet to be fully determined whether the vaccine protects against severe disease caused by the highly transmissible coronavirus variant found in South Africa.
Addressing the country digitally, the Prime Minister said that India managed to make two 'Made-in-India' vaccines in a very short period which usually takes years.
The British star developed Mr Bean while he was studying for his master's degree at Oxford University and launched the character on television in the 1990.
The Brazilian Association of Vaccine Clinics (ABCVAC) confirmed on its website it had signed a memorandum of understanding with the Indian firm to purchase its Covaxin vaccine
This regimen was shown in clinical trials to be safe and effective at preventing symptomatic Covid-19, with no severe cases and no hospitalisations more than 14 days after the second dose, according to AstraZeneca.
Hyderabad: Employability is not the only purpose of education, it should facilitate a solution to the problems faced by the society said Prof Mohammad...
Modi began his three-city visit on Saturday to review coronavirus vaccine development work by going to pharma major Zydus Cadila's manufacturing facility near Ahmedabad in the morning.
Zydus Cadila had announced that the phase-I clinical trial of its vaccine candidate ZyCoV-D was over and it has commenced phase-II clinical trials from August.
The study, published in The Lancet medical journal, suggest that those aged over 70 -- who are at higher risk of serious illness and death from Covid-19 -- could build robust immunity to the novel Coronavirus.
The team is also testing whether the vaccine stops people developing COVID-19 in larger Phase 3 trials and early results from this crucial stage are expected in the coming weeks.
12Page 1 of 2
- Advertisement -